I. Paul Singh

1 month ago | eyetube.net | I. Paul Singh |Darrell E. White

Innovations in Ophthalmic Practice: Work-Life Balance I. Paul Singh, MD; and Darrell E. White, MD Show Description + Darrell E. White, MD, joins I. Paul Singh, MD, on a special episode of Innovation Journal Club dedicated to the topic of work-life balance. According to Dr. White, the key to achieving balance lies not in separating professional responsibilities and personal life, but rather in finding harmony between these two worlds.

1 month ago | eyetube.net | I. Paul Singh |Denise M. Visco

Innovations in Astigmatism Management: Long-term Stability of Arcuate Incisions I. Paul Singh, MD; and Denise M. Visco, MD, MBA Show Description + In this episode of Innovation Journal Club, I. Paul Singh, MD, interviews Denise Visco, MD, MBA, about using the LENSAR ALLY femtosecond laser for making arcuate incisions for astigmatism correction during cataract surgery. Dr. Visco emphasizes the importance of precision, axis alignment, and incision consistency.

2 months ago | eyetube.net | I. Paul Singh

Innovations in Glaucoma: Procedural Pharmaceuticals I. Paul Singh, MD; and Steven R. Sarkisian Jr, MD Show Description + Steven R. Sarkisian Jr., MD, joins I. Paul Singh, MD, on Innovation Journal Club to discuss the impact of procedural pharmaceuticals on glaucoma management. Along with a review of a recent study on the topic, the two discuss how the advent of procedural pharmaceuticals enables a more proactive approach.

Mar 18, 2025 | healio.com | I. Paul Singh |Anthony DeFino |Christine Klimanskis

Read more ORLANDO — In this Healio Video Perspective from Telling It Like It Is, I. Paul Singh, MD, shares how Dextenza can decrease the topical drop burden of steroids and improve efficiency of ophthalmic surgery. According to Singh, Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) reduces the amount of time ophthalmologists spend on patient education and follow-up, as well as time spent in discussions with insurance companies and pharmacies.

Mar 1, 2025 | eyetube.net | I. Paul Singh |Carl D. Regillo

Innovations in AMD Therapy: Second-Generation Anti-VEGFs I. Paul Singh, MD; and Carl D. Regillo, MD Show Description + In this episode of Innovation Journal Club, Carl Regillo, MD, and I. Paul Singh, MD, discuss outcomes from phase 3 studies of faricimab-svoa (Vabysmo, Genentech) and aflibercept 8 mg (Eyelea HD, Regeneron) in neovascular AMD. According to Dr. Regillo, the data suggests that these agents achieve greater durability and a better drying effect than first-generation anti-VEGF drugs.